Evidence map›Paper›PMID 26155923›Full record

Trial reportClinical and translational science2015

Quantification of Aerosol Hydrofluoroalkane HFA-134a Elimination in the Exhaled Human Breath Following Inhaled Corticosteroids Administration.

Hye-Won Shin, Barbara Barletta, Leila Yoonessi, Simone Meinardi, Szu-Yun Leu, Shlomit Radom-Aizik, Inderpal Randhawa, Eliezer Nussbaum, Donald R Blake, Dan M Cooper

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical and translational science, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Hye-Won ShinDepartment of Pediatrics and Pediatrics Exercise Center, University of California, Irvine, Irvine, California, USA.
Barbara BarlettaDepartment of Chemistry, University of California, Irvine, Irvine, California, USA.
Leila YoonessiMiller Children's Hospital, Orange, California, USA.
Simone MeinardiDepartment of Chemistry, University of California, Irvine, Irvine, California, USA.
Szu-Yun LeuDepartment of Pediatrics and Pediatrics Exercise Center, University of California, Irvine, Irvine, California, USA.
Shlomit Radom-AizikDepartment of Pediatrics and Pediatrics Exercise Center, University of California, Irvine, Irvine, California, USA.
Inderpal RandhawaMiller Children's Hospital, Orange, California, USA.
Eliezer NussbaumMiller Children's Hospital, Orange, California, USA.
Donald R BlakeDepartment of Chemistry, University of California, Irvine, Irvine, California, USA.
Dan M CooperDepartment of Pediatrics and Pediatrics Exercise Center, University of California, Irvine, Irvine, California, USA.
University of California, Irvine · USBoston Children's Hospital · US

Funding

University of California Health Participation in the National COVID Cohort Collaborative (N3C)UL1TR001414 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI COOPER, DAN M, VILAIN, ERIC J. · 2015 to 2023
$35.1M
Peripheral Blood Mononuclear Cells, Exercise, and Children: Initial MechanismsP01HD048721 · NICHD · UNIVERSITY OF CALIFORNIA-IRVINE · PI COOPER, DAN M · 2006 to 2016
$13.6M
Institute for Clinical and Translational ScienceUL1TR000153 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI COOPER, DAN M · 2012 to 2015
$12.1M
INSTITUTE FOR CLINICAL AND TRANSLATIONAL SCIENCEUL1RR031985 · NCRR · UNIVERSITY OF CALIFORNIA-IRVINE · PI COOPER, DAN M · 2010 to 2011
$7.2M
NCATS NIH HHS UL1 TR000153NCATS NIH HHS UL1 TR001414NCRR NIH HHS UL1 RR031985NICHD NIH HHS P01 HD048721NICHD NIH HHS P01HD048721
6 · The paper itself

Abstract

Inhaled corticosteroids (ICS) and β2-agonists are the primary pharmacotherapies of asthma management. However, suboptimal medication compliance is common in asthmatics and is associated with increased morbidity. We hypothesized that exhaled breath measurements of the aerosol used in the inhaled medications might prove useful as surrogate marker for asthma medication compliance. To explore this, 10 healthy controls were recruited and randomly assigned to ICS (Flovent HFA) or short acting bronchodilators (Proventil HFA). Both inhalers contain HFA-134a as aerosol propellant. Exhaled breath sampling and pulmonary function tests were performed prior to the inhaler medication dispersion, immediately after inhalation, then at 2, 4, 6, 8, 24, and 48 hours postadministration. At baseline, mean (SD) levels of HFA-134a in the breath were 252 (156) pptv. Immediately after inhalation, HFA-134a breath levels increased to 300 × 10(6) pptv and were still well above ambient levels 24 hours postadministration. The calculated ratio of forced expiratory volume in 1 second over forced vital capacity did not change over time following inhaler administration. This study demonstrates, for the first time, that breath HFA-134a levels can be used to assess inhaler medication compliance. It may also be used to evaluate how effectively the medicine is delivered.

Indexed as

Breath TestsExhalationMedication AdherenceAdministration, InhalationAdrenal Cortex HormonesAdultAerosol PropellantsAerosolsAlbuterolBronchodilator AgentsCaliforniaChemistry, PharmaceuticalDrug MonitoringFemaleFluorocarbonsFluticasoneAdrenal Cortex HormonesAerosol PropellantsAerosolsAlbuterolapafluraneBronchodilator AgentsFluorocarbonsFluticasoneHydrocarbons, Fluorinated1,1,1,2-TetrafluoroethaneaerosolAlbuterol inhalerasthmabronchodilatorcompliancegas chromatographyHFA-134ahydrofluoroalkaneinhaled corticosteroids (ICS)propellant

Identifiers

PMID26155923
PMCPMC4626293
OpenAlexW1550720887

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.